AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study Examining The Effect Of Renal Impairment On Safety, Toleration And How The Body Processes An Experimental Drug

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: CP-945,598

First Posted Date: 2007-05-14

Last Posted Date: 2009-08-13

Lead Sponsor: Pfizer

Target Recruit Count: 17

Registration Number: NCT00472836

Locations: 🇺🇸
Pfizer Investigational Site, Miami, Florida, United States

A Study To Investigate The Ability To Use 18FDG PET Scanning To Monitor The Effectiveness Of New Drugs In COPD Patients

Terminated

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Procedure: PET imaging

First Posted Date: 2007-05-11

Last Posted Date: 2009-07-02

Lead Sponsor: Pfizer

Target Recruit Count: 20

Registration Number: NCT00472264

Locations: 🇺🇸
Pfizer Investigational Site, St. Louis, Missouri, United States

Nasopharyngeal Streptococcus Pneumoniae Carriage

Completed

Conditions: Streptococcus Pneumoniae Infections

First Posted Date: 2007-05-10

Last Posted Date: 2013-11-20

Lead Sponsor: Pfizer

Target Recruit Count: 9707

Registration Number: NCT00471822

Locations: 🇨🇳
Pfizer Investigational Site, Taoyuan, Taiwan

Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

Phase 3

Completed

Conditions: Carcinoma, Pancreatic Ductal

Interventions: Drug: AG-013736
Drug: Gemcitabine
Drug: placebo

First Posted Date: 2007-05-09

Last Posted Date: 2012-07-16

Lead Sponsor: Pfizer

Target Recruit Count: 630

Registration Number: NCT00471146

Locations: 🇬🇧
Pfizer Investigational Site, Southhampton, United Kingdom

Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer

Phase 2

Completed

Conditions: Breast Neoplasms

Interventions: Drug: sunitinib

First Posted Date: 2007-05-09

Last Posted Date: 2011-07-25

Lead Sponsor: Pfizer

Target Recruit Count: 83

Registration Number: NCT00471276

Locations: 🇺🇸
Pfizer Investigational Site, Everett, Washington, United States

A Prospective Safety Follow Up Study Of Subjects Enrolled In Study A4321001 And Who Have Received Drug Product

Completed

Conditions: Siderosis

Interventions: Other: Observational Trial

First Posted Date: 2007-05-09

Last Posted Date: 2011-02-17

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT00471224

Locations: 🇺🇸
Pfizer Investigational Site, Houston, Texas, United States

Study of Five Different Methods Of Delivering A Lifestyle Modification Program for Weight Loss

Not Applicable

Completed

Conditions: Obesity

First Posted Date: 2007-05-09

Last Posted Date: 2008-09-15

Lead Sponsor: Pfizer

Target Recruit Count: 350

Registration Number: NCT00471172

Locations: 🇺🇸
Pfizer Investigational Site, Milwaukee, Wisconsin, United States

A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.

Phase 2

Withdrawn

Conditions: Breast Neoplasms

First Posted Date: 2007-05-09

Last Posted Date: 2015-05-04

Lead Sponsor: Pfizer

Registration Number: NCT00471159

A Blinded Study To Examine The Ability Of PF-610,355 To Open The Airways In Asthmatic Patients.

Phase 2

Completed

Conditions: Asthma

First Posted Date: 2007-05-03

Last Posted Date: 2010-11-01

Lead Sponsor: Pfizer

Target Recruit Count: 42

Registration Number: NCT00468975

Locations: 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom

Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer's Disease

Not Applicable

Completed

Conditions: Alzheimer Disease
Caregivers

First Posted Date: 2007-05-01

Last Posted Date: 2007-05-07

Lead Sponsor: Pfizer

Target Recruit Count: 300

Registration Number: NCT00467766

Locations: 🇺🇸
Aging and Dementia Research Center, Silberstein Institute, NYU School of Medicine, New York, New York, United States
🇦🇺
Prince of Wales Hospital, Randwick, New South Wales, Australia
🇬🇧
University of Manchester, Division of Psychiatry, Manchester, United Kingdom

Home Terms & Conditions Privacy Policy